Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 DNA Aβ42 vaccination as possible alternative immunotherapy for Alzheimer disease.

Literature DB >> 23700123

DNA Aβ42 vaccination as possible alternative immunotherapy for Alzheimer disease.

Roger N Rosenberg¹, Doris Lambracht-Washington.

Abstract

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2013 PMID： 23700123 PMCID： PMC4077322 DOI： 10.1001/jamaneurol.2013.1502

Source DB: PubMed Journal: JAMA Neurol ISSN： 2168-6149 Impact factor: 18.302

× No keyword cloud information.

14 in total

1. DNA beta-amyloid(1-42) trimer immunization for Alzheimer disease in a wild-type mouse model.

Authors: Doris Lambracht-Washington; Bao-Xi Qu; Min Fu; Todd N Eagar; Olaf Stüve; Roger N Rosenberg
Journal: JAMA Date: 2009-10-28 Impact factor: 56.272

2. DNA immunization against amyloid beta 42 has high potential as safe therapy for Alzheimer's disease as it diminishes antigen-specific Th1 and Th17 cell proliferation.

Authors: Doris Lambracht-Washington; Bao-Xi Qu; Min Fu; Larry D Anderson; Olaf Stüve; Todd N Eagar; Roger N Rosenberg
Journal: Cell Mol Neurobiol Date: 2011-04-06 Impact factor: 5.046

3. Gene vaccination to bias the immune response to amyloid-beta peptide as therapy for Alzheimer disease.

Authors: Baoxi Qu; Roger N Rosenberg; Liping Li; Philip J Boyer; Stephen A Johnston
Journal: Arch Neurol Date: 2004-12

Review 4. Translational research on the way to effective therapy for Alzheimer disease.

Authors: Roger N Rosenberg
Journal: Arch Gen Psychiatry Date: 2005-11

5. Active DNA Aβ42 vaccination as immunotherapy for Alzheimer disease.

Authors: Doris Lambracht-Washington; Roger N Rosenberg
Journal: Transl Neurosci Date: 2012-12-01 Impact factor: 1.757

6. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse.

Authors: D Schenk; R Barbour; W Dunn; G Gordon; H Grajeda; T Guido; K Hu; J Huang; K Johnson-Wood; K Khan; D Kholodenko; M Lee; Z Liao; I Lieberburg; R Motter; L Mutter; F Soriano; G Shopp; N Vasquez; C Vandevert; S Walker; M Wogulis; T Yednock; D Games; P Seubert
Journal: Nature Date: 1999-07-08 Impact factor: 49.962

7. A peptide prime-DNA boost immunization protocol provides significant benefits as a new generation Aβ42 DNA vaccine for Alzheimer disease.

Authors: Doris Lambracht-Washington; Bao-xi Qu; Min Fu; Larry D Anderson; Todd N Eagar; Olaf Stüve; Roger N Rosenberg
Journal: J Neuroimmunol Date: 2012-10-01 Impact factor: 3.478

DNA Aβ42 vaccination as possible alternative immunotherapy for Alzheimer disease.

1. DNA beta-amyloid(1-42) trimer immunization for Alzheimer disease in a wild-type mouse model.

2. DNA immunization against amyloid beta 42 has high potential as safe therapy for Alzheimer's disease as it diminishes antigen-specific Th1 and Th17 cell proliferation.

3. Gene vaccination to bias the immune response to amyloid-beta peptide as therapy for Alzheimer disease.

Review 4. Translational research on the way to effective therapy for Alzheimer disease.

5. Active DNA Aβ42 vaccination as immunotherapy for Alzheimer disease.

6. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse.

7. A peptide prime-DNA boost immunization protocol provides significant benefits as a new generation Aβ42 DNA vaccine for Alzheimer disease.

8. Abeta42 gene vaccine prevents Abeta42 deposition in brain of double transgenic mice.

9. Abeta42 gene vaccination reduces brain amyloid plaque burden in transgenic mice.

10. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial.

1. From the genetic code to neuromics.